Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.37 Insider Own12.43% Shs Outstand7.22M Perf Week-16.57%
Market Cap10.18M Forward P/E- EPS next Y-1.46 Insider Trans0.00% Shs Float6.32M Perf Month-29.15%
Income-19.20M PEG- EPS next Q-0.67 Inst Own6.10% Short Float1.92% Perf Quarter-33.18%
Sales0.20M P/S50.90 EPS this Y41.18% Inst Trans-19.30% Short Ratio2.17 Perf Half Y11.90%
Book/sh1.05 P/B1.35 EPS next Y30.71% ROA-97.88% Short Interest0.12M Perf Year-62.41%
Cash/sh1.35 P/C1.04 EPS next 5Y- ROE-119.64% 52W Range0.79 - 4.18 Perf YTD11.02%
Dividend Est.- P/FCF- EPS past 5Y-23.31% ROI-280.92% 52W High-66.28% Beta1.38
Dividend TTM- Quick Ratio2.55 Sales past 5Y49.79% Gross Margin8.71% 52W Low78.48% ATR (14)0.16
Dividend Ex-Date- Current Ratio2.55 EPS Y/Y TTM19.02% Oper. Margin-10285.34% RSI (14)34.33 Volatility8.51% 9.35%
Employees8 Debt/Eq0.03 Sales Y/Y TTM38.08% Profit Margin-9797.30% Recom1.00 Target Price15.50
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q24.91% Payout- Rel Volume0.29 Prev Close1.53
Sales Surprise- EPS Surprise7.59% Sales Q/Q-100.00% EarningsMay 16 BMO Avg Volume55.88K Price1.41
SMA20-19.61% SMA50-19.96% SMA200-15.39% Trades Volume15,930 Change-7.84%
Jun-05-24 08:05AM
May-20-24 08:01AM
May-19-24 08:09AM
May-16-24 06:52AM
May-15-24 08:00PM
08:45AM Loading…
May-09-24 08:00AM
Apr-18-24 04:30PM
Apr-03-24 08:05AM
Apr-02-24 10:25AM
Mar-28-24 09:06PM
Mar-27-24 10:53PM
Mar-07-24 08:30AM
Feb-28-24 04:05PM
09:55AM Loading…
Feb-15-24 09:55AM
Feb-07-24 07:55AM
Jan-29-24 09:05AM
Jan-22-24 12:00PM
Jan-16-24 04:05PM
Dec-19-23 08:30AM
Dec-04-23 08:35AM
Nov-14-23 04:30PM
Nov-07-23 09:28AM
Oct-16-23 07:00AM
Oct-04-23 08:30AM
Sep-20-23 08:30AM
Aug-24-23 08:30AM
Aug-22-23 08:05AM
08:30AM Loading…
Aug-21-23 08:30AM
Aug-17-23 08:30AM
Aug-15-23 11:47PM
Aug-14-23 04:20PM
Aug-07-23 08:05AM
Jul-17-23 04:05PM
Jun-29-23 09:29AM
Jun-22-23 08:05AM
Jun-21-23 08:05AM
May-30-23 08:05AM
May-24-23 12:04PM
May-17-23 06:11AM
May-16-23 07:45AM
May-15-23 08:30AM
May-09-23 07:15AM
May-08-23 08:05AM
May-04-23 08:05AM
May-02-23 03:30PM
Apr-26-23 08:00AM
Apr-24-23 09:00AM
Apr-21-23 08:30AM
Apr-07-23 10:25PM
Mar-31-23 08:22AM
Mar-23-23 05:15PM
Mar-21-23 08:00AM
Mar-16-23 08:30AM
Mar-15-23 08:35AM
Mar-08-23 08:30AM
Feb-15-23 04:05PM
Feb-08-23 01:00PM
Jan-27-23 04:05PM
Jan-25-23 01:00PM
Dec-12-22 04:05PM
Dec-07-22 04:05PM
Nov-22-22 08:00AM
Nov-14-22 05:45PM
Nov-10-22 05:00AM
Nov-08-22 08:00AM
Nov-07-22 08:00AM
Oct-12-22 08:00AM
Sep-21-22 04:05PM
Sep-15-22 08:00AM
Sep-13-22 12:15PM
Sep-08-22 08:30AM
Sep-01-22 04:05PM
Aug-26-22 08:00AM
Aug-23-22 08:00AM
Aug-12-22 04:55PM
Aug-08-22 08:30AM
Jun-13-22 08:00AM
May-16-22 05:00PM
May-10-22 08:05AM
May-09-22 04:05PM
Apr-21-22 04:05PM
Apr-13-22 11:45AM
Apr-06-22 11:37AM
Mar-31-22 05:00PM
Mar-28-22 08:00AM
Mar-25-22 08:00AM
Mar-23-22 08:00AM
Mar-08-22 08:00AM
Jan-05-22 08:30AM
Nov-29-21 08:05AM
Nov-15-21 05:30PM
Oct-27-21 08:05AM
Oct-19-21 08:05AM
Oct-04-21 09:57AM
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.